Wednesday, January 25, 2017 7:11:06 PM
Veritas Pharma Places Final Payment In Trust For
The Acquisition Of Cannevert Therapeutics
January 25, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, has announced that it has placed its final payment of $250,000 to Cannevert Therapeutics Ltd. (CTL) (scheduled for May 1st, 2017) into a trust account. The completion of this payment will bring Veritas’ investment in CTL up to $1,500,000 granting an 80% ownership of CTL, with an option to purchase the additional 20%.
Completion of this transaction will enable CTL to focus on applying for further non-dilutive funding through various research grant applications. CTL has previously shown success in receiving grants. On October 20th, 2016, Veritas Pharma announced awarding of MITACS grant to CTL.
Veritas CEO, Dr. Franciosi, commented “We are excited to proceed rapidly and to solidify our agreement with Cannevert. As I have mentioned previously, the Cannevert scientists are a very capable team with a proven track record of creating substantial shareholder value. It is good to see that both Cannevert and Veritas are now well funded to further accelerate the scientific screening and identification of new products for the clinic.”
When asked about other upcoming milestones for the company, Dr. Franciosi commented, “We will be reviewing Cannevert’s current research progress as well as focusing on our Access to Cannabis for Medical Purposes Regulations (ACMPR) application, which are eagerly awaiting Health Canada’s decision. This was filed on July 4th 2014. Since then, we delivered on all their information requests and have been in good standing. We recently inquired about our status and we should be hearing back from them shortly.”
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging discovery and IP development company, committed to advancing the science behind medical cannabis. The company’s current R&D efforts are being conducted through its strategic partner, Cannevert Therapeutics Ltd. (“CTL”). The ultimate objectives of our R&D efforts are to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for real science to support medical marijuana claims.
About Cannevert Therapeutics Ltd.
CTL is a private company owned by a unique group of chemists, pharmacologists, and other medical science professionals. With offices located on the campus of the University of British Columbia, CTL has obtained permission from Health Canada to conduct research on cannabis strains. CTL has entered a funding agreement with Veritas where, upon advancing $1.5 million to CTL, Veritas will earn an 80% ownership interest in CTL. To date, Veritas has advanced $750,000 to CTL and holds contingent ownership of, but not the voting rights over, 40.5% of the issued and outstanding common shares of CTL. Veritas will not acquire full ownership rights, including voting rights, over any CTL common shares until the entire $1.5 million has been paid. CTL has also entered a licensing agreement with Veritas, licensing Veritas to market all products developed by CTL.
Veritas’ and CTL’s unique value proposition employs a whole plant methodology, using a low cost research and development model to help drive shareholder value and speed-to-market. The company’s commercial mission is to patent protect its IP (cultivars/ strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.
Veritas Pharma Inc. is a publicly traded company, which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: veritaspharmainc.com
On behalf of the Board of Directors; Veritas Pharma Inc.
Dr. Lui Franciosi
Chief Executive Officer
Recent VRT News
- Vertiv to Participate in Upcoming Conferences • Business Wire • 04/29/2024 12:00:00 PM
- U.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures Trading • IH Market News • 04/24/2024 11:31:20 AM
- Vertiv Reports 60% Organic Orders Growth, 8% Net Sales Growth in First Quarter; Updates Full Year 2024 Outlook • Business Wire • 04/24/2024 09:55:00 AM
- Vertiv Announces Date of First Quarter 2024 Earnings Release and Conference Call • Business Wire • 04/10/2024 12:00:00 PM
- Vertiv Unveils End-to-End AI Power and Cooling Solutions to Simplify Data Center Infrastructure Selection and Deployment in North America • Business Wire • 04/04/2024 09:36:00 PM
- Vertiv Joins the NVIDIA Partner Network • Business Wire • 03/18/2024 10:07:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:55:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:33:12 PM
- Vertiv Declares Quarterly Dividend • Business Wire • 03/07/2024 09:20:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 02:01:32 AM
- Vertiv to Participate in Upcoming J.P. Morgan Industrials Conference • Business Wire • 03/04/2024 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2024 12:45:43 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 11:02:03 AM
- Vertiv Reports Strong Fourth Quarter Results and Provides Full Year 2024 Outlook • Business Wire • 02/21/2024 10:55:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 10:01:03 PM
- Vertiv Announces Date of Fourth Quarter and Full Year 2023 Earnings Release and Conference Call • Business Wire • 01/31/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:31:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 12:28:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 12:27:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 12:27:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 12:27:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 12:27:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 12:26:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 12:26:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 12:26:32 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM